内分泌治疗对乳腺癌患者骨密度影响的研究进展

Research progress of the effect of endocrine therapy on bone mineral density in patients with breast cancer

雌、孕激素受体(ER、PR)阳性的浸润性乳腺癌患者,均应接受内分泌治疗。内分泌治疗疗效好,但有其相应的不良反应,骨密度(bone mineral density,BMD)降低是内分泌治疗的主要不良反应之一。本文主要介绍乳腺癌内分泌治疗对患者骨密度的影响方面研究进展。

Endocrine therapy usually should be implemented to invasive breast cancer patients with hormone receptor-positive （ER, PR）. Clinical efficacy of endocrine therapy is good, while relvant side effects also exist. The decrease of bone mineral density （BMD） is one of the main side effects in patients receiving endocrine therapy. This paper mainly focuses on the research progress of the effect of endocrine therapy on BMD of patients with breast cancer.